Intuitive Surgical, Inc. (ISRG)
Intuitive Surgical: Buy The January Selloff
Intuitive Surgical remains a compelling long-term buy despite recent share price weakness and mixed Q4 results. Da Vinci 5 adoption is robust, with 74% YoY system placement growth and expanding FDA-approved use cases. 2026 guidance is soft, with procedure growth expected to slow to 13–15%, but headwinds are seen as temporary.
Is Intuitive Surgical (ISRG) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Bull of the Day: Intuitive Surgical (ISRG)
Never bet against the da Vinci surgical system.
ISRG's da Vinci Gets FDA Nod for Advanced Cardiac Procedures
Intuitive Surgical wins FDA 510(k) clearance for the da Vinci 5 system in select cardiac procedures to expand minimally invasive heart surgery.
China Remains Competitive: Can ISRG Defend Share Amid Local Rivals?
ISRG faces slower China tenders, local favoritism and pricing pressure, even as clinicians prefer da Vinci and management flags 2026 competition.
Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
ISRG Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Declines
Intuitive Surgical stock gains after Q4 EPS and revenue top estimates as system placements and procedure growth offset a decline in gross margin.
Intuitive Surgical Just Proved the Growth Engine Still Runs
Robotic-assisted surgery stalwart Intuitive Surgical NASDAQ: ISRG blew investors away with its Q3 2025 earnings report back in October 2025. Shares closed up nearly 14% in reaction to the results, marking the healthcare stock's largest single-day post-earnings gain in recent memory.
Intuitive Surgical (ISRG) Reports Q4 Earnings: What Key Metrics Have to Say (Revised)
Although the revenue and EPS for Intuitive Surgical (ISRG) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
More Upside For ISRG Stock?
Intuitive Surgical reported strong Q4 2025 outcomes with adjusted EPS of $2.53, exceeding estimates of $2.26 and increasing by 14.5% from Q4 2024's $2.21. Revenue reached $2.87 billion, a 19% increase year-over-year that surpassed the consensus of $2.75 billion, while full-year revenue hit $10.1 billion (+21%) coupled with adjusted EPS of $8.93.
Intuitive Surgical (ISRG) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Intuitive Surgical (ISRG) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Intuitive Surgical, Inc. (ISRG) Q4 2025 Earnings Call Transcript
Intuitive Surgical, Inc. (ISRG) Q4 2025 Earnings Call Transcript
